
Opinion|Videos|December 20, 2024
Dosing Frequency, and Adverse Event Management With Bispecific Therapy
Panelists discuss how an early adverse event for this drug class no matter what the mechanism or target is, is cytokine release syndrome (CRS), and it tends to occur on a timescale that is predictable. When treating patients in the outpatient setting, they receive dexamethasone, given at the first fever, which is the first sign of cytokine release syndrome (CRS) and helps mitigate it.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- Can you describe the CRS and ICANS that we see with the bispecifics, both BCMA and GPRC5D, and how we are approaching treating these patients in the inpatient and outpatient setting?
Advertisement
Advertisement
Advertisement
Trending on CancerNetwork
1
Daraxonrasib/Vopimetostat Yield Stunning Response Rate in MTAP-del Pancreatic Cancer
2
Melanoma Trials You May Have Missed at ASCO 2026
3
80 Datopotamab Deruxtecan (Dato-DXd) + Durvalumab (D) as First-Line (1L) Treatment (tx) for Unresectable Locally Advanced/Metastatic Triple-Negative Breast Cancer (a/mTNBC): Final Results From the Phase 1b/2 BEGONIA Study
4
Subcutaneous Isatuximab Earns EU Approval in Multiple Myeloma
5




































































